Drug Discovery@nature.com 6 April 2012

Advertisement Pre-cloned promoter and 3'UTR reporter assays The LightSwitch Luciferase Assay System provides everything you need for reporter assays: pre-cloned human promoters and 3'UTRs in luciferase reporter vectors plus optimized luciferase reagents to measure promoter induction and miRNA target validation. Visit SwitchGear Genomics and explore our genome-wide collections and validated pathway sets. TABLE OF CONTENTS 6 April 2012 News Analysis Research Highlights Research & Reviews Careers Nature Reviews Drug Discovery is on Twitter Advertisement Nature Reviews Cancer & Nature Reviews Immunology FOCUS ON TUMOUR IMMUNOLOGY & IMMUNOTHERAPY Access the Focus online for FREE until end of September 2012: http://www.nature.com/reviews/focus/tumourimmunology Produced with support from Boehringer Ingelheim   News Top Moving towards a universal flu vaccine doi:10.1038/nature.2012.10333 Israeli company reports good results with supplemental shot in elderly. Full Text Unleashing the Mini-Sentinel doi:10.1038/nrd3713 First data from the FDA's new active surveillance programme highlight how the system might influence drug development programmes. Full Text Hedgehog inhibitor gets landmark skin cancer approval, but questions remain for wider potential doi:10.1038/nrd3714 Approval for Genentech's vismodegib marked the first approval for a Hedgehog inhibitor, but questions remain for the class's broader role in other cancers. Full Text Market watch: Upcoming market catalysts in Q2 2012 doi:10.1038/nrd3707 Highlights include approval decisions on phentermine/topiramate combination therapy for obesity, and on linaclotide for irritable bowel syndrome and chronic idiopathic constipation. Trial data for interferon-free treatment regimens for hepatitis C virus infection are also expected. Full Text Analysis Top Memory is skin deep doi:10.1038/scibx.2012.322 A Harvard Medical School team has identified a T cell–based immune response in the skin that is better at protecting mice from some viral infections than circulating T cells. Trem Rx is developing a vaccine platform against infectious diseases and cancer based on these results. Full Text Fresh from the Pipeline: Aflibercept doi:10.1038/nrd3700 Fusion protein that inhibits vascular endothelial growth factor signalling approved in the United States for the treatment of neovascular age-related macular degeneration. Full Text From the analyst's couch: Rare diseases and orphan drugs doi:10.1038/nrd3654 This article discusses market trends in the development of drugs for rare diseases, which have increasingly been recognized as providing attractive opportunities for the biopharmaceutical industry. Full Text Research Highlights Top Neuromuscular disorders: Troponin activator improves muscle function doi:10.1038/nrd3703 A small-molecule activator of the troponin complex increased skeletal muscle strength in a rodent model of neuromuscular disease. Full Text Neurological disorders: A class of its own doi:10.1038/nrd3704 A potential new class of drugs offers enhanced selectivity and efficacy over the drugs that are currently used in the clinic to treat absence seizures. Full Text Immunotherapy: Combinations that work doi:10.1038/nrc3250 Preclinical data support the strategy of combining tumour-targeted therapies with immune-stimulating agents. Full Text Research & Reviews Top Novel molecular targets for atrial fibrillation therapy doi:10.1038/nrd3682 This Review focuses on the mechanistic rationale for the development of new anti-atrial fibrillation drugs, on the molecular and structural motifs that they target and on the results obtained so far in experimental and clinical studies. Full Text Combining immunotherapy and targeted therapies in cancer treatment doi:10.1038/nrc3237 This article outlines how combining targeted approaches, which inhibit molecular pathways that promote tumour growth and maintenance, with immunotherapy, which stimulates a host immune response that effectuates long-lived tumour destruction, could provide therapeutic synergy. Full Text A proteomics approach for the identification and cloning of monoclonal antibodies from serum doi:10.1038/nbt.2167 Cheung et al. couple proteomics with next-generation sequencing of RNA from B cells to clone antibodies directly from the sera of immunized rabbits and mice, potentially advancing immunology and vaccinology research and the development of therapeutics. Full Text Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma doi:10.1038/nbt.2157 Pulido et al. identify specific tumor-associated antigens from tumor-derived virus-expressed cDNA libraries that can be used in combination to cure established melanoma in mice. Full Text Drug Discovery JOBS of the week The deaths from taking drugs: retrospective and prospective case study and definition of methodological protocols in Forensic Medicine Unimore Effects of new antiarhythmic drugs on thyroid homeostasis Università di Pisa - Dipartimento di Endocrinologia e Metabolismo, Ortopedia e Traumatologia, Medicina del Lavoro Effects of drugs inhibiting the signal transduction pathway PI3K / AKT / mTOR in cell lines of breast cancer Università degli Studi Implications in clinical behavior and drug-resistance of CLL crosstalk with microenvironment Unimore Drug Discovery Sales Specialist San Diego Area 1975 EMD Millipore US More Science jobs from Drug Discovery EVENT 6th Drug Design & Medicinal Chemistry 07.-08.06.12 CA, US More science events from Careers Top Career snapshots archive Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field. Full Text Top Advertisement SciBX: Science-Business eXchange is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why. Recommend SciBX to your library today.   Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.